[go: up one dir, main page]

WO2018005328A8 - Deuterated bictegravir - Google Patents

Deuterated bictegravir Download PDF

Info

Publication number
WO2018005328A8
WO2018005328A8 PCT/US2017/039207 US2017039207W WO2018005328A8 WO 2018005328 A8 WO2018005328 A8 WO 2018005328A8 US 2017039207 W US2017039207 W US 2017039207W WO 2018005328 A8 WO2018005328 A8 WO 2018005328A8
Authority
WO
WIPO (PCT)
Prior art keywords
bictegravir
deuterated
deuterium
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/039207
Other languages
French (fr)
Other versions
WO2018005328A1 (en
Inventor
Roger D. Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of WO2018005328A1 publication Critical patent/WO2018005328A1/en
Publication of WO2018005328A8 publication Critical patent/WO2018005328A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to deuterated forms of bictegravir, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4a, Y4b, Y5a, Y5b, Y6, Y7a, Y7b, Y8, Y9, Y10a, Y10b, Y11a, and Y11b is independently hydrogen or deuterium; provided that if each Y1, Y2, Y3, Y4a, Y4b, Y5a, Y5b, Y6, Y7a, Y7b, Y8, Y9, Y10a, Y10b, and Y11 a is hydrogen, then Y11b is deuterium.
PCT/US2017/039207 2016-06-27 2017-06-26 Deuterated bictegravir Ceased WO2018005328A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662355105P 2016-06-27 2016-06-27
US62/355,105 2016-06-27

Publications (2)

Publication Number Publication Date
WO2018005328A1 WO2018005328A1 (en) 2018-01-04
WO2018005328A8 true WO2018005328A8 (en) 2018-02-15

Family

ID=60787625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/039207 Ceased WO2018005328A1 (en) 2016-06-27 2017-06-26 Deuterated bictegravir

Country Status (1)

Country Link
WO (1) WO2018005328A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862325B (en) * 2018-08-28 2020-08-25 重庆博腾制药科技股份有限公司 Preparation method of (1R,3S) -3-amino-1-cyclopentanol and salt thereof
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
CN110229174A (en) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 The synthetic method of Bictegravir bulk pharmaceutical chemicals genotoxicity impurity
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151361A1 (en) * 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
PH12019501848A1 (en) * 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
WO2018005328A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MX2015002040A (en) Deuterated baricitinib.
MX2015001246A (en) Deuterated ibrutinib.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
TN2018000262A1 (en) Substituted piperidine compound and use there of.
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
WO2016011390A8 (en) Irak4 inhibiting agents
PH12019500480A1 (en) Pyridine compound
HK1249893A1 (en) Deuterated vx-661
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
WO2016014927A3 (en) Crystalline form of nicotinamide riboside
WO2015168286A8 (en) Substituted 4-phenylpiperidines, their preparaiton and use
MX2016002794A (en) Antiproliferative compounds.
MX2018003554A (en) Isoxazoline-substituted benzamides and analogues as insecticides.
WO2015000431A9 (en) Tizoxanide carbamate and pharmaceutical use thereof
MX2015008829A (en) Deuterated momelotinib.
PH12015502118A1 (en) Pyridin-4-yl derivatives
WO2018005328A8 (en) Deuterated bictegravir
WO2014153495A9 (en) Novel stat3 inhibitors
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
MX359069B (en) Salt and crystal forms of plk-4 inhibitor.
EA201700356A1 (en) NEW CYCLOPROPANBENZOFURANILPYRIDOPYRAZINDIONS
MY193239A (en) Novel b-lactamase inhibitors
WO2015002755A3 (en) Compounds for the treatment of malaria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17820996

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17820996

Country of ref document: EP

Kind code of ref document: A1